Weizhi Zhike's domestically produced targeted nuclear drug 177Lu-PSMA-VG01 has been approved for clinical use
On November 28, 2025, according to the official website of the National Medical Products Administration's Center for Drug Evaluation (NMPA CDE), Shandong Weizhi Zhike Pharmaceutical Co., Ltd. (hereinafter referred to as "Weizhi Zhike", VitsGen) independently developed a Class 1 radiotherapy drug, 177Lu-PSMA-VG01 Injection, which has obtained clinical trial implied permission (acceptance number: CXHL2501015), intended for the treatment of metastatic castration resistant prostate cancer (mCPRC) positive for prostate-specific membrane antigen (PSMA).
Weizhi Zhike has independently developed 177Lu-PSMA-VG01 injection, in which PSMA-VG01 can target and bind to the surface of PSMA positive cells, and enter the cells during receptor circulation. Subsequently, 177Lw transmits radiation to cells expressing PSMA and surrounding cells through decay released particles, inducing DNA damage and leading to cell death. 177Lu-PSMA-VG01 injection has shown significant differentiation advantages in in vitro and in vivo non clinical studies, achieving performance improvements in multiple dimensions compared to similar marketed drugs
High affinity and rapid internalization characteristics: The binding affinity between the drug and PSMA targets is increased by 2.6 times, the cellular internalization efficiency is increased by 2.4 times, and it can be more efficiently enriched at the tumor site.
Long term retention and precise clearance: It can achieve longer retention and sustained killing in tumor tissues, while the uptake level is lower in normal tissues such as kidneys, indicating better safety.
Mechanism driven therapeutic potential: Its innovative molecular design is expected to bring better tumor clearance effects and lower risk of toxic side effects, providing new treatment hope for advanced prostate cancer patients.
The first oral GLP-1R/GIPR/GCGR triple target agonist peptide ASC37 from Geli is undergoing clinical development
On November 30, 2025, Geli Pharmaceutical Co., Ltd. (Hong Kong Stock Exchange code: 1672, abbreviated as "Geli" Yibu) has selected its first oral GLP-1R/GIPR/GCGR triple target agonist peptide ASC37 oral tablet as a clinical development candidate drug. Geli is expected to submit a new drug clinical trial application (ND) for ASC37 oral tablets for the treatment of obesity to the US Food and Drug Administration (FDA) in the second quarter of 2026.
ASC37 oral tablets are the first candidate drug for incretin developed by our company using our proprietary Peptide Oral Transport Enhancement Technology (POTEND).
ASC37 is a GLP-1R, GIPR, and GCGR triple target agonist peptide that was independently discovered and optimized using the Artificial Intelligence Assisted Structure Based Drug Discovery (AISBDD) technology of Geli. In vitro experiments have shown that ASC37 is approximately 5 times, 4 times, and 4 times stronger than retatrutide in terms of its excitatory activity towards GLP-1R, GIPR, and GCGR, respectively.
In head to head studies of non-human primates, the average absolute oral bioavailability of ASC37 oral tablets was 4.2% using the Geli POTENT technique, which is approximately 9 times, 30 times, and 60 times higher than that of semaglutide, cilostatin, and retatrutide using oral SNAC formulation technology, respectively. In addition, in head to head studies of non-human primates, after oral administration, the drug exposure of ASC37 oral tablets (POTENT formulation) was approximately 57 times that of retatrutide (oral SNAC formulation) in terms of area under the drug time curve (AUC).
Re Jing Biotechnology collaborates with related parties to increase capital in Yaojing Gene, betting on the small nucleic acid drug track
On December 2, 2025, Rejing Biotechnology announced that the company, along with Lin Changqing and Beijing Yaojing Enterprise Management Center (Limited Partnership) (hereinafter referred to as "Yaochen Partnership"), intends to jointly increase the capital of Beijing Yaojing Gene Technology Co., Ltd. (hereinafter referred to as "Yaochen Gene"). The capital increase plan is that Rejing Biotechnology will contribute 24 million yuan, Lin Changqing will contribute 50 million yuan, and Yaochen Partnership will contribute 6 million yuan, totaling 80 million yuan, at a price of 2 yuan per registered capital.
After the completion of this capital increase, the registered capital of Yaojing Gene has been changed from 110 million yuan to 150 million yuan, and the company's shareholding in Yaojing Gene has been changed from 40.91% to 38.00%.
In July 2025, Yaojing Gene's small nucleic acid drug patent for targeted PLN therapy for heart failure was granted, successfully breaking through the limitations of traditional treatment methods that can only delay disease progression but cannot reverse pathological changes. By precisely regulating PLN expression, it can effectively restore SERCA2a activity, improve myocardial calcium circulation, and directly target the core pathological mechanism of heart failure. It is expected to achieve a leap from symptom control to etiological treatment, bringing new hope for improving patient survival rates. In August 2025, Yaojing Gene was officially granted a patent for "siRNA and its conjugates and applications that inhibit APP gene expression", which is a small nucleic acid drug patent for the treatment of Alzheimer's disease.
Helicore terminates clinical trials of first GIP antagonist and restarts pipeline layout
On December 2, 2025, Helicore Biopharma, a biopharmaceutical company focused on discovering and developing a first of its kind glucose dependent insulinotropic peptide (GIP) antagonist for the treatment of obesity and related diseases, announced the termination of clinical trials for its GIP antagonist HCR-188 and plans to shift its focus to other obesity syndrome drugs in its research and development pipeline.
The company announced in January this year that it had obtained $65 million in Series A funding, originally intended to support the research and development of HCR-188. In March, the company launched a phase one clinical trial in Australia and stated that it will obtain safety data by the end of this year.
However, according to updated information from the US Federal Clinical Trial Registry, the company has suspended the trial. According to a spokesperson, the company will shift from monoclonal antibody HCR-188 to its preclinical research and development pipeline for glucagon like peptide-1 (inclitin) conjugates.
HCR-188 is a clinical stage monoclonal antibody designed to bind to GIP. HCR-188 binds to circulating GIP ligands, not GIP receptors. Helicore hopes this will differentiate it from similar therapies, including MariTide from Amgen and a drug being developed by Antag, by reducing circulating GIP and blocking its signaling in the brain. Anjin's drug is currently one of the most anticipated next-generation obesity treatment drugs.
MariTide (AMG133) is an innovative long-acting peptide antibody conjugate that is a specific GLP-1R agonist and GIPR antagonist. By promoting insulin secretion, suppressing appetite, and delaying gastric emptying, significant weight loss and improved blood sugar control can be achieved. In addition, by inhibiting the GIPR signal, the enhancing effect of GIP on insulin secretion is reduced, while the metabolic improvement ability of GLP-1 activation is enhanced.
The clinical trial of RAY1225 MASH, an innovative peptide drug of Zhongsheng Ruichuang, has been approved
On December 4, 2025, Guangdong Zhongsheng Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company"), a subsidiary of Guangdong Zhongsheng Kechuang Biotechnology Co., Ltd. (hereinafter referred to as "Zhongsheng Ruichuang"), independently developed an innovative peptide drug RAY1225 Injection for the treatment of "metabolic related steatohepatitis". The drug clinical trial was approved by the National Medical Products Administration and received the<>, agreeing to conduct clinical trials for the new indication of RAY1225 Injection.
RAY1225 injection is an innovative structural peptide drug developed by Zhongsheng Ruichuang with global independent intellectual property rights. It has dual agonist activity of GLP-1 receptor and GIP receptor, and thanks to its excellent pharmacokinetic properties, it has the potential for long-acting drug injection once every two weeks. At present, the phase clinical trial on the safety and efficacy of RAY1225 injection for the treatment of obese/overweight patients in China (REBUILDING-2 study) has been successfully launched and all participants have been enrolled; The safety and effectiveness of RAY1225 injection in the single drug treatment of type 2 diabetes patients, the placebo controlled Phase I clinical trial (SHING-2), the safety and effectiveness of RAY1225 injection in the combined treatment of type 2 semiuria patients with oral hypoglycemic drugs, and the Phase I clinical trial of Smeaglutide injection control (SHNING-3), the two phase I clinical trials of hypoglycemic drugs, have been successfully enrolled.